Despite recent progress made in early diagnosis of prostate cancer, medical advice is sought mostly at locally advanced stage. Both surgery and radiotherapy (distant or contact) are used. Yet, such methods have limited application, namely, in patients with basal level of prostate-specific antigen (PSA) under 50 ng/ml, without distant metastases. Even in those with excess of that value and without apparent distant metastases, i.e. cases at high risk of tumor process generalization, local treatment may be carried out on a limited scale. Tentative data are discussed on the results of combined treatment of such a group of patients as, compared with hormone therapy.